Dynavax Technologies Corporation Stock News

Here is how Dynavax Technologies (DVAX) and Omnicell (OMCL) have performed compared to their sector so far this year.

One analyst gets notably more bullish on the biotech's shares.

Shares of Dynavax Technologies Co. (NASDAQ:DVAX) were down 3.9% during mid-day trading on Wednesday . The company traded as low as $13.66 and last traded at $13.68. Approximately 5,540 shares traded hands during trading, a decline of 100% from the average daily volume of 3,946,220 shares. The stock had previously closed at $14.23. Several research […]

Equities analysts expect Dynavax Technologies Co. (NASDAQ:DVAX) to announce earnings of $0.65 per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for Dynavax Technologies earnings. The highest EPS estimate is $0.73 and the lowest is $0.57. Dynavax Technologies reported earnings of ($0.14) per share in the same quarter []

Dynavax Technologies Corporation (NASDAQ:DVAX) concluded the trading at $14.04 on Wednesday, December 22 with a fall of -1.34% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $14.23 and 5Y monthly beta was reading 1.32 with its price kept floating in the An Analysis Of Dynavax Technologies Corporations (DVAX) Stock Behavior Read More »

The biotech sector has been in focus through 2021 as vaccine makers like Moderna (MRNA) BioNTech (BNTX), and other companies like Dynavax (DVAX), Prothena (PRTA) and Intellia (NTLA) put up an exemplar

Wall Street brokerages expect Dynavax Technologies Co. (NASDAQ:DVAX) to announce $214.65 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for Dynavax Technologies earnings. The highest sales estimate is $230.90 million and the lowest is $198.40 million. Dynavax Technologies reported sales of $19.55 million in the []

F M Investments LLC acquired a new stake in Dynavax Technologies Co. (NASDAQ:DVAX) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 12,495 shares of the biopharmaceutical companys stock, valued at approximately $240,000. Other large investors also recently made changes to their positions in []

Brokerages forecast that Dynavax Technologies Co. (NASDAQ:DVAX) will post earnings per share (EPS) of $0.65 for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Dynavax Technologies earnings, with the lowest EPS estimate coming in at $0.57 and the highest estimate coming in at $0.73. Dynavax Technologies posted earnings of ($0.14) []

The small cap biotech space offers a powerful dimension for active investors because it is comprised of stocks with little or no consistent correlation with the broad market, creating diversification without sacrificing explosive upside potential. But the group is best handled in baskets. In other words, investors may stand to benefit from cultivating exposure to [] The post Top Ideas in the Small Cap Biotech Space (INMB, OTLC, DVAX, SAVA, ICPT, IMGN) appeared first on Wall Street PR .

Dynavax Technologies Co. (NASDAQ:DVAX) Equities researchers at William Blair increased their FY2021 earnings estimates for shares of Dynavax Technologies in a research report issued on Wednesday, December 1st. William Blair analyst M. Phipps now forecasts that the biopharmaceutical company will post earnings of $1.01 per share for the year, up from their previous estimate []

Wall Street brokerages forecast that Dynavax Technologies Co. (NASDAQ:DVAX) will report earnings per share of $0.65 for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for Dynavax Technologies’ earnings. The lowest EPS estimate is $0.57 and the highest is $0.73. Dynavax Technologies reported earnings of ($0.14) per share in the same […]

Dynavax Technologies Co. (NASDAQ:DVAX) Equities researchers at William Blair lifted their Q4 2021 earnings estimates for Dynavax Technologies in a report released on Wednesday, December 1st. William Blair analyst M. Phipps now expects that the biopharmaceutical company will post earnings per share of $0.73 for the quarter, up from their previous forecast of $0.69. []

These second-tier COVID-19 vaccine players plunged due to fears about the potential impacts of the omicron variant.

The biotech stock is being pulled down by the broader market sell-off.